DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes. / Deacon, Carolyn F; Carr, Richard D; Holst, Jens Juul.
In: Frontiers in Bioscience, Vol. 13, 2008, p. 1780-94.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes
AU - Deacon, Carolyn F
AU - Carr, Richard D
AU - Holst, Jens Juul
N1 - Keywords: Animals; Antigens, CD26; Diabetes Mellitus, Type 2; Disease Models, Animal; Enzyme Inhibitors; Gastric Inhibitory Polypeptide; Glucose; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Islets of Langerhans; Mice; Rats
PY - 2008
Y1 - 2008
N2 - Many patients with type 2 diabetes fail to achieve adequate glycaemic control with available treatments, even when used in combination, and eventually develop microvascular and macrovascular diabetic complications. Even intensive interventions to control glycaemia reduce macrovascular complications only minimally. There is, therefore, a need for new agents that more effectively treat the disease, as well as target its prevention, its progression, and its associated complications. One emerging area of interest is centred upon the actions of the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which enhance meal-induced insulin secretion and have trophic effects on the beta-cell. GLP-1 also inhibits glucagon secretion, and suppresses food intake and appetite. Two new classes of agents have recently gained regulatory approval for therapy of type 2 diabetes; long-acting stable analogues of GLP-1, the so-called incretin mimetics, and inhibitors of dipeptidyl peptidase 4 (DPP-4, the enzyme responsible for the rapid degradation of the incretin hormones), the so-called incretin enhancers. This article focuses on DPP-4 inhibitors.
AB - Many patients with type 2 diabetes fail to achieve adequate glycaemic control with available treatments, even when used in combination, and eventually develop microvascular and macrovascular diabetic complications. Even intensive interventions to control glycaemia reduce macrovascular complications only minimally. There is, therefore, a need for new agents that more effectively treat the disease, as well as target its prevention, its progression, and its associated complications. One emerging area of interest is centred upon the actions of the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which enhance meal-induced insulin secretion and have trophic effects on the beta-cell. GLP-1 also inhibits glucagon secretion, and suppresses food intake and appetite. Two new classes of agents have recently gained regulatory approval for therapy of type 2 diabetes; long-acting stable analogues of GLP-1, the so-called incretin mimetics, and inhibitors of dipeptidyl peptidase 4 (DPP-4, the enzyme responsible for the rapid degradation of the incretin hormones), the so-called incretin enhancers. This article focuses on DPP-4 inhibitors.
M3 - Journal article
C2 - 17981667
VL - 13
SP - 1780
EP - 1794
JO - Frontiers in Bioscience
JF - Frontiers in Bioscience
SN - 1093-9946
ER -
ID: 8933143